Abstract: Psoriasis is a common, chronic inflammatory disease with a variety of comorbidities involving psoriatic arthritis (PsA), cardiovascular diseases, metabolic syndrome (MS), inflammatory bowel disease (IBD) and psychological disease. Psoriasis and its comorbidities may share a common pathogenic pathway, so biological agents which are designed to inhibit specific molecular targets of immune responses can have an impact on comorbidities by changing systemic inflammatory state. The update of the treatment of biological agents on psoriasis comorbidities is reviewed in this paper.

Key words: biological agents, psoriasis, comorbidities